{"id":"cggv:254975f0-b3ae-4838-909a-17db2e9faabcv1.1","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:254975f0-b3ae-4838-909a-17db2e9faabc_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10005","date":"2024-09-17T17:00:00.000Z","role":"Approver"},{"id":"cggv:254975f0-b3ae-4838-909a-17db2e9faabc_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10005","date":"2024-10-14T14:19:45.456Z","role":"Publisher"}],"curationReasons":{"id":"cg:NewCuration"},"evidence":[{"id":"cggv:254975f0-b3ae-4838-909a-17db2e9faabc_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:3da10bce-ec24-48eb-8414-f9f8c5873ceb_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:3da10bce-ec24-48eb-8414-f9f8c5873ceb","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":4,"allele":{"id":"cggv:8ce143f0-ef8a-453e-9c5c-8b04eaeddcc8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014334.4(FRRS1L):c.692G>A (p.Trp231Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10575813"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0002378","obo:HP_0100248","obo:HP_0002179","obo:HP_0001252","obo:HP_0002072","obo:HP_0002376","obo:HP_0010864","obo:HP_0031165"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:11dab278-53f5-4592-b6da-b3acbe7d6522_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:8ce143f0-ef8a-453e-9c5c-8b04eaeddcc8"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/27236917","type":"dc:BibliographicResource","dc:abstract":"Glutamatergic neurotransmission governs excitatory signaling in the mammalian brain, and abnormalities of glutamate signaling have been shown to contribute to both epilepsy and hyperkinetic movement disorders. The etiology of many severe childhood movement disorders and epilepsies remains uncharacterized. We describe a neurological disorder with epilepsy and prominent choreoathetosis caused by biallelic pathogenic variants in FRRS1L, which encodes an AMPA receptor outer-core protein. Loss of FRRS1L function attenuates AMPA-mediated currents, implicating chronic abnormalities of glutamatergic neurotransmission in this monogenic neurological disease of childhood.","dc:creator":"Madeo M","dc:date":"2016","dc:title":"Loss-of-Function Mutations in FRRS1L Lead to an Epileptic-Dyskinetic Encephalopathy."}},"rdfs:label":"2-II-1"},{"id":"cggv:11dab278-53f5-4592-b6da-b3acbe7d6522","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:11dab278-53f5-4592-b6da-b3acbe7d6522_variant_evidence_item"},{"id":"cggv:11dab278-53f5-4592-b6da-b3acbe7d6522_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Reduced protein in patient fibroblast."}],"strengthScore":1,"dc:description":"This variant is expected to escape nonsense-mediated decay. However, they showed reduced protein levels in patient-derived fibroblast, we are awarding one point per allele. "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:254975f0-b3ae-4838-909a-17db2e9faabc_seg_el","type":"EvidenceLine","specifiedBy":"GeneValiditySegregationEvidencCriteria","strengthScore":3},{"id":"cggv:628804ed-f86a-40b8-9476-aeddbc084b40_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:628804ed-f86a-40b8-9476-aeddbc084b40","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":11,"allele":{"id":"cggv:d1343cf2-45d0-472d-88e8-8915a6f23cf0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014334.4(FRRS1L):c.808C>T (p.Gln270Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10575812"}},"detectionMethod":"First autozygome analysis using Aziom array and AutoSNPa revealed a single interval (chr9: 111623055-119811790, hg 19) exclusive to the affected members, which was confirmed by linkage analysis. Exome sequencing revealed the homozygous variant that completely segregated with the disease. ","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Linkage analysis","phenotypes":["obo:HP_0031491","obo:HP_0002353","obo:HP_0002376","obo:HP_0012758","obo:HP_0001250"],"previousTesting":false,"secondTestingMethod":"Exome sequencing","sex":"Female","variant":{"id":"cggv:94244ba1-4069-4ce7-a7a5-d522ee893b77_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d1343cf2-45d0-472d-88e8-8915a6f23cf0"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/27239025","type":"dc:BibliographicResource","dc:creator":"Shaheen R","dc:date":"2016","dc:title":"Epileptic encephalopathy with continuous spike-and-wave during sleep maps to a homozygous truncating mutation in AMPA receptor component FRRS1L."}},"rdfs:label":"F1-IV-4"},{"id":"cggv:94244ba1-4069-4ce7-a7a5-d522ee893b77","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:94244ba1-4069-4ce7-a7a5-d522ee893b77_variant_evidence_item"},{"id":"cggv:94244ba1-4069-4ce7-a7a5-d522ee893b77_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Failed coassembly with GluA1/A2 Fig. 4D in PMID 28675162 and reduced protein in patient-derived fibroblast in PMID: 27236917\n"}],"strengthScore":1.5,"dc:description":"The variant escapes nonsense-mediated decay. However, since there are functional studies and this variant has been seen repeatedly in other studies (PMID: 27236917, 28675162, 27239025, 31054490), we are awarding 1.5 points per allele. "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:78e02200-9c2f-473e-be1e-937882acb260_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:78e02200-9c2f-473e-be1e-937882acb260","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":2,"allele":{"id":"cggv:d1343cf2-45d0-472d-88e8-8915a6f23cf0"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001250","obo:HP_0002376","obo:HP_0010864","obo:HP_0001252","obo:HP_0001263"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:6d1544cd-9183-4c52-9245-5d514e19b256_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d1343cf2-45d0-472d-88e8-8915a6f23cf0"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/28675162","type":"dc:BibliographicResource","dc:abstract":"AMPA-type glutamate receptors (AMPARs), key elements in excitatory neurotransmission in the brain, are macromolecular complexes whose properties and cellular functions are determined by the co-assembled constituents of their proteome. Here we identify AMPAR complexes that transiently form in the endoplasmic reticulum (ER) and lack the core-subunits typical for AMPARs in the plasma membrane. Central components of these ER AMPARs are the proteome constituents FRRS1l (C9orf4) and CPT1c that specifically and cooperatively bind to the pore-forming GluA1-4 proteins of AMPARs. Bi-allelic mutations in the human FRRS1L gene are shown to cause severe intellectual disability with cognitive impairment, speech delay and epileptic activity. Virus-directed deletion or overexpression of FRRS1l strongly impact synaptic transmission in adult rat brain by decreasing or increasing the number of AMPARs in synapses and extra-synaptic sites. Our results provide insight into the early biogenesis of AMPARs and demonstrate its pronounced impact on synaptic transmission and brain function.","dc:creator":"Brechet A","dc:date":"2017","dc:title":"AMPA-receptor specific biogenesis complexes control synaptic transmission and intellectual ability."}},"rdfs:label":"C-II-3"},{"id":"cggv:6d1544cd-9183-4c52-9245-5d514e19b256","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:6d1544cd-9183-4c52-9245-5d514e19b256_variant_evidence_item"},{"id":"cggv:6d1544cd-9183-4c52-9245-5d514e19b256_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Failed coassembly with GluA1/A2 Fig. 4D in PMID 28675162\n"}],"strengthScore":0,"dc:description":"Unsure whether this individual overlaps with individuals in PMID: 31054490. Furthermore, this variant has been seen as homozygous in multiple studies and is suspected to be a Saudi founder variant (PMID: 27236917, 28675162, 27239025, 31054490). "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:3f07dc3d-8e85-4240-b9c2-c19d4c10a3e3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:3f07dc3d-8e85-4240-b9c2-c19d4c10a3e3","type":"Proband","allele":{"id":"cggv:65759f55-8547-4559-94be-9133c1f38344","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014334.4(FRRS1L):c.246dup (p.Phe83LeufsTer22)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2580079401"}},"detectionMethod":"Indication-based exome","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0200134","obo:HP_0012758"],"previousTesting":false,"sex":"UnknownEthnicity","variant":{"id":"cggv:efe2bbb0-e7d0-46f8-b4da-ebe21abb30c0_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:65759f55-8547-4559-94be-9133c1f38344"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/36703223","type":"dc:BibliographicResource","dc:abstract":"Rare diseases collectively impose a significant burden on healthcare systems, especially in underserved regions, like the Middle East, which lack access to genomic diagnostic services and the associated personalized management plans.","dc:creator":"El Naofal M","dc:date":"2023","dc:title":"The genomic landscape of rare disorders in the Middle East."}},"rdfs:label":"Patient 1"},{"id":"cggv:efe2bbb0-e7d0-46f8-b4da-ebe21abb30c0","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:efe2bbb0-e7d0-46f8-b4da-ebe21abb30c0_variant_evidence_item"}],"strengthScore":1,"dc:description":"The variant was homozygous. "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:8a01d859-71a3-4289-b03f-9361b2aeecac_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:8a01d859-71a3-4289-b03f-9361b2aeecac","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":7,"allele":{"id":"cggv:879c76cc-10b3-431b-a3d3-aa15a3fa463c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014334.4(FRRS1L):c.462G>T (p.Met154Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5177411"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001249","obo:HP_0002353","obo:HP_0032792","obo:HP_0032794","obo:HP_0002069","obo:HP_0012758"],"previousTesting":false,"sex":"Male","variant":{"id":"cggv:56670c32-ddc9-44e6-9189-921a3af48f4e_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:879c76cc-10b3-431b-a3d3-aa15a3fa463c"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/33584793","type":"dc:BibliographicResource","dc:abstract":"Lennox-Gastaut syndrome (LGS) is a severe type of childhood-onset epilepsy characterized by multiple types of seizures, specific discharges on electroencephalography, and intellectual disability. Most patients with LGS do not respond well to drug treatment and show poor long-term prognosis. Approximately 30% of patients without brain abnormalities have unidentifiable causes. Therefore, accurate diagnosis and treatment of LGS remain challenging. To identify causative mutations of LGS, we analyzed the whole-exome sequencing data of 17 unrelated Korean families, including patients with LGS and LGS-like epilepsy without brain abnormalities, using the Genome Analysis Toolkit. We identified 14 mutations in 14 genes as causes of LGS or LGS-like epilepsy. 64 percent of the identified genes were reported as LGS or epilepsy-related genes. Many of these variations were novel and considered as pathogenic or likely pathogenic. Network analysis was performed to classify the identified genes into two network clusters: neuronal signal transmission or neuronal development. Additionally, knockdown of two candidate genes with insufficient evidence of neuronal functions, ","dc:creator":"Yang JO","dc:date":"2021","dc:title":"Characteristics of Genetic Variations Associated With Lennox-Gastaut Syndrome in Korean Families."}},"rdfs:label":"10-II:1"},{"id":"cggv:56670c32-ddc9-44e6-9189-921a3af48f4e","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:56670c32-ddc9-44e6-9189-921a3af48f4e_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:c9e89222-7e92-4941-b54b-f344c8f4735a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:c9e89222-7e92-4941-b54b-f344c8f4735a","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":24,"allele":{"id":"cggv:d98e6834-d9fe-4734-b0bb-6fef042e9ac4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014334.4(FRRS1L):c.584_586del (p.Gly195del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10575814"}},"ethnicity":{"id":"cg:HispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000565","obo:HP_0001252","obo:HP_0010864","obo:HP_0001250","obo:HP_0002072","obo:HP_0011097","obo:HP_0002396","obo:HP_0002376","obo:HP_0000639","obo:HP_0001347"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:339d5af6-18a8-4b4e-9af1-840237f3d7f0_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d98e6834-d9fe-4734-b0bb-6fef042e9ac4"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/27236917"},"rdfs:label":"3-II-1"},{"id":"cggv:339d5af6-18a8-4b4e-9af1-840237f3d7f0","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:339d5af6-18a8-4b4e-9af1-840237f3d7f0_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:2f395b06-1fe2-4664-bcc3-8305e7d7e4f0_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:2f395b06-1fe2-4664-bcc3-8305e7d7e4f0","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":0,"allele":{"id":"cggv:d6c89310-1412-43bb-b6dd-fdc432e73b0f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014334.4(FRRS1L):c.145del (p.Asp49ThrfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA197584981"}},"ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Whole genome shotgun sequencing","phenotypes":["obo:HP_0000938","obo:HP_0002376","obo:HP_0006892","obo:HP_0000545","obo:HP_0002180","obo:HP_0010864","obo:HP_0012469","obo:HP_0001252","obo:HP_0001250","obo:HP_0011471","obo:HP_0001336"],"previousTesting":false,"sex":"Male","variant":{"id":"cggv:bf45c134-52c9-4a60-ac6d-f5bbc74494fd_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d6c89310-1412-43bb-b6dd-fdc432e73b0f"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/30525197","type":"dc:BibliographicResource","dc:abstract":"[Image: see text]","dc:creator":"Thuresson AC","dc:date":"2019","dc:title":"Whole genome sequencing of consanguineous families reveals novel pathogenic variants in intellectual disability."}},"rdfs:label":"3"},{"id":"cggv:bf45c134-52c9-4a60-ac6d-f5bbc74494fd","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:bf45c134-52c9-4a60-ac6d-f5bbc74494fd_variant_evidence_item"}],"strengthScore":1,"dc:description":"Homozygous variant."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:b3520c62-0944-466b-874f-c5680a002079_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:b3520c62-0944-466b-874f-c5680a002079","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":12,"allele":{"id":"cggv:d1343cf2-45d0-472d-88e8-8915a6f23cf0"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Homozygosity mapping","phenotypes":["obo:HP_0002376","obo:HP_0200134","obo:HP_0002069"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:79d41e74-de20-4f59-9cdb-4fde6c43161e_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d1343cf2-45d0-472d-88e8-8915a6f23cf0"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/31054490","type":"dc:BibliographicResource","dc:abstract":"Epileptic encephalopathies (EE), are a group of age-related disorders characterized by intractable seizures and electroencephalogram (EEG) abnormalities that may result in cognitive and motor delay. Early infantile epileptic encephalopathies (EIEE) manifest in the first year of life. EIEE are highly heterogeneous genetically but a genetic etiology is only identified in half of the cases, typically in the form of de novo dominant mutations.","dc:creator":"Nashabat M","dc:date":"2019","dc:title":"The landscape of early infantile epileptic encephalopathy in a consanguineous population."}},"rdfs:label":"KF39-F"},{"id":"cggv:79d41e74-de20-4f59-9cdb-4fde6c43161e","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:79d41e74-de20-4f59-9cdb-4fde6c43161e_variant_evidence_item"},{"id":"cggv:79d41e74-de20-4f59-9cdb-4fde6c43161e_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Reduced protein levels in patient fibroblast in PMID: 27236917. Failed coassembly with GluA1/A2 Fig. 4D in PMID 28675162. "}],"strengthScore":0,"dc:description":"This variant is expected to escape nonsense-mediated decay. Furthermore, it has been seen as homozygous in multiple studies (PMID: 27236917, 28675162, 27239025, 31054490) and is suspected to be a Saudi founder variant. "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:e986fff8-afbe-4c0a-9be9-de3db2cc3840_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:e986fff8-afbe-4c0a-9be9-de3db2cc3840","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":21,"allele":{"id":"cggv:21968ff9-271d-40b8-94c6-bf2a54849755","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014334.4(FRRS1L):c.310A>G (p.Lys104Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA374428028"}},"detectionMethod":"WES was done on  all affected individuals (II.1, II.4., II.5) and their healthy parent","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001250","obo:HP_0004322","obo:HP_0002342","obo:HP_0001263"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:40cc6c7a-788d-4f11-9c8e-4bd41a1ad19b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:21968ff9-271d-40b8-94c6-bf2a54849755"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28675162"},"rdfs:label":"A-II-1"},{"id":"cggv:40cc6c7a-788d-4f11-9c8e-4bd41a1ad19b","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:40cc6c7a-788d-4f11-9c8e-4bd41a1ad19b_variant_evidence_item"},{"id":"cggv:40cc6c7a-788d-4f11-9c8e-4bd41a1ad19b_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"coassembly with GluA1/A2 less effective."}],"strengthScore":0.1,"dc:description":"The functional data is not convincing"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:a93f5b17-6e28-4925-ae09-752f45566363_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:a93f5b17-6e28-4925-ae09-752f45566363","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":3,"allele":{"id":"cggv:2555a446-4b82-4767-baf0-2e51b400dfcc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014334.4(FRRS1L):c.431del (p.Val144GlufsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1139661129"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001250","obo:HP_0010864","obo:HP_0001263","obo:HP_0001252","obo:HP_0002376"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:9d8ca7f0-28ff-4b17-a46f-2c5f114a4ce4_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:2555a446-4b82-4767-baf0-2e51b400dfcc"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28675162"},"rdfs:label":"B-II-7"},{"id":"cggv:9d8ca7f0-28ff-4b17-a46f-2c5f114a4ce4","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:9d8ca7f0-28ff-4b17-a46f-2c5f114a4ce4_variant_evidence_item"}],"strengthScore":1,"dc:description":"Homozygous in a consanguineous family"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:7fa54d59-0b29-4975-9d3d-b879c39519f1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:7fa54d59-0b29-4975-9d3d-b879c39519f1","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":7,"allele":{"id":"cggv:cf00b8e4-e94e-404b-8391-4b3630872b38","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014334.4(FRRS1L):c.625C>T (p.Pro209Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA374424010"}},"ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000252","obo:HP_0001263","obo:HP_0001250"],"previousTesting":false,"sex":"Male","variant":{"id":"cggv:57f0ea2e-9749-4494-b5a0-c5f9bc7f6059_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:cf00b8e4-e94e-404b-8391-4b3630872b38"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/31130284","type":"dc:BibliographicResource","dc:abstract":"We report the results of clinical exome sequencing (CES) on >2,200 previously unpublished Saudi families as a first-tier test. The predominance of autosomal-recessive causes allowed us to make several key observations. We highlight 155 genes that we propose to be recessive, disease-related candidates. We report additional mutational events in 64 previously reported candidates (40 recessive), and these events support their candidacy. We report recessive forms of genes that were previously associated only with dominant disorders and that have phenotypes ranging from consistent with to conspicuously distinct from the known dominant phenotypes. We also report homozygous loss-of-function events that can inform the genetics of complex diseases. We were also able to deduce the likely causal variant in most couples who presented after the loss of one or more children, but we lack samples from those children. Although a similar pattern of mostly recessive causes was observed in the prenatal setting, the higher proportion of loss-of-function events in these cases was notable. The allelic series presented by the wealth of recessive variants greatly expanded the phenotypic expression of the respective genes. We also make important observations about dominant disorders; these observations include the pattern of de novo variants, the identification of 74 candidate dominant, disease-related genes, and the potential confirmation of 21 previously reported candidates. Finally, we describe the influence of a predominantly autosomal-recessive landscape on the clinical utility of rapid sequencing (Flash Exome). Our cohort's genotypic and phenotypic data represent a unique resource that can contribute to improved variant interpretation through data sharing.","dc:creator":"Monies D","dc:date":"2019","dc:title":"Lessons Learned from Large-Scale, First-Tier Clinical Exome Sequencing in a Highly Consanguineous Population."}},"rdfs:label":"18-2393"},{"id":"cggv:57f0ea2e-9749-4494-b5a0-c5f9bc7f6059","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:57f0ea2e-9749-4494-b5a0-c5f9bc7f6059_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:28d91b53-e915-44a1-9204-c415bdb92cc7_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:28d91b53-e915-44a1-9204-c415bdb92cc7","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":6,"allele":{"id":"cggv:34669345-4967-4647-a403-66f816fa9687","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014334.4(FRRS1L):c.283dup (p.Ile95AsnfsTer10)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10575815"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0010864","obo:HP_0002072","obo:HP_0001252","obo:HP_0020221","obo:HP_0002376","obo:HP_0001336"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:3edf5c0b-6631-470c-9791-a611742b4a7d_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:34669345-4967-4647-a403-66f816fa9687"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/27236917"},"rdfs:label":"4-II-2"},{"id":"cggv:3edf5c0b-6631-470c-9791-a611742b4a7d","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:3edf5c0b-6631-470c-9791-a611742b4a7d_variant_evidence_item"}],"strengthScore":1,"dc:description":"homozygous variant in consanguineous family"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:254975f0-b3ae-4838-909a-17db2e9faabc_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":12},{"id":"cggv:05be9417-56ec-415e-b4de-33073af7d56c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:05be9417-56ec-415e-b4de-33073af7d56c","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","allele":{"id":"cggv:d9c8b1ce-34fd-4bca-8248-ad5735eee56b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014334.4(FRRS1L):c.227dup (p.Ser77ValfsTer28)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2695211021"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000347","obo:HP_0002015","obo:HP_0002353","obo:HP_0025405","obo:HP_0012758","obo:HP_0001266","obo:HP_0000218","obo:HP_0000316","obo:HP_0005280","obo:HP_0009890","obo:HP_0000369","obo:HP_0030890","obo:HP_0002266","obo:HP_0001290"],"previousTesting":false,"sex":"Female","variant":{"id":"cggv:512c8e40-a5f7-4813-a470-22077992a4e7_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d9c8b1ce-34fd-4bca-8248-ad5735eee56b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/35815844","type":"dc:BibliographicResource","dc:creator":"Mir A","dc:date":"2023","dc:title":"Continuous Spikes and Waves During Sleep (CSWS), Severe Epileptic Encephalopathy, and Choreoathetosis due to Mutations in "}},"rdfs:label":"2"},{"id":"cggv:512c8e40-a5f7-4813-a470-22077992a4e7","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:512c8e40-a5f7-4813-a470-22077992a4e7_variant_evidence_item"}],"strengthScore":0,"dc:description":"Homozygous in a consanguineous family. There is another family with the same variant from the same country (Saudi Arabia), and it may represent the same family. "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:f01cf7df-cc88-4e47-a882-c6b071b01f91_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:f01cf7df-cc88-4e47-a882-c6b071b01f91","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":0,"allele":{"id":"cggv:d9c8b1ce-34fd-4bca-8248-ad5735eee56b"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0006813","obo:HP_0001266","obo:HP_0025405","obo:HP_0000325","obo:HP_0000490","obo:HP_0002353","obo:HP_0002553","obo:HP_0012758","obo:HP_0002069","obo:HP_0001347","obo:HP_0000252","obo:HP_0001290","obo:HP_0003487","obo:HP_0000341","obo:HP_0002169","obo:HP_0007270"],"previousTesting":false,"sex":"Female","variant":{"id":"cggv:753c70cd-8ddf-4b2a-ab45-0838143e49e5_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d9c8b1ce-34fd-4bca-8248-ad5735eee56b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/35815844"},"rdfs:label":"1"},{"id":"cggv:753c70cd-8ddf-4b2a-ab45-0838143e49e5","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:753c70cd-8ddf-4b2a-ab45-0838143e49e5_variant_evidence_item"}],"strengthScore":1,"dc:description":"Homozygous in a consanguineous family"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:560c6a1d-a082-47a8-80ec-91d5ebf6e058_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:560c6a1d-a082-47a8-80ec-91d5ebf6e058","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":18,"allele":{"id":"cggv:d1343cf2-45d0-472d-88e8-8915a6f23cf0"},"detectionMethod":"homozygous regions shared by affected individuals but absent in unaffected individuals in family 1 were identified with Affymetrix Whole-Genome CytoScan HD SNP arrays according to the manufacturerâ€™s instructions. We identified six >3 Mb homozygous regions shared by affected family members alone. They performed whole-exome sequencing on individuals\n1_II-1 to 1_II-4 and focused our analysis on homozygous stop-gain, stop-loss, or frameshift and splice-site or missense variants predicted to be deleterious..","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Homozygosity mapping","phenotypes":["obo:HP_0001252","obo:HP_0010864","obo:HP_0002375","obo:HP_0002069","obo:HP_0002506","obo:HP_0002072","obo:HP_0002376","obo:HP_0002063","obo:HP_0001257"],"previousTesting":false,"secondTestingMethod":"Exome sequencing","sex":"Female","variant":{"id":"cggv:0ac98262-9dcc-405e-9429-76dba10a8036_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d1343cf2-45d0-472d-88e8-8915a6f23cf0"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/27236917"},"rdfs:label":"1-II-1"},{"id":"cggv:0ac98262-9dcc-405e-9429-76dba10a8036","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:0ac98262-9dcc-405e-9429-76dba10a8036_variant_evidence_item"},{"id":"cggv:0ac98262-9dcc-405e-9429-76dba10a8036_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Reduced protein in patient fibroblast. Failed coassembly with GluA1/A2 Fig. 4D in PMID 28675162"}],"strengthScore":0,"dc:description":"This variant has been seen repeatedly in other publications and is considered a possible Saudi founder variant (PMID: 27236917, 28675162, 27239025, 31054490)."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:da30e8d1-2d2f-4c9e-be24-82ecf19b5e93_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:da30e8d1-2d2f-4c9e-be24-82ecf19b5e93","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":9,"allele":{"id":"cggv:d1343cf2-45d0-472d-88e8-8915a6f23cf0"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0002376","obo:HP_0002069","obo:HP_0200134"],"previousTesting":false,"sex":"Male","variant":{"id":"cggv:b2601e59-d479-49dd-965b-6a1589bd4b93_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d1343cf2-45d0-472d-88e8-8915a6f23cf0"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31054490"},"rdfs:label":"KF35-E"},{"id":"cggv:b2601e59-d479-49dd-965b-6a1589bd4b93","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:b2601e59-d479-49dd-965b-6a1589bd4b93_variant_evidence_item"},{"id":"cggv:b2601e59-d479-49dd-965b-6a1589bd4b93_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Reduced protein levels in patient fibroblast in PMID: 27236917. Failed coassembly with GluA1/A2 Fig. 4D in PMID 28675162"}],"strengthScore":0,"dc:description":"This variant is expected to escape nonsense-mediated decay. Furthermore, it has been seen as homozygous in multiple studies (PMID: 27236917, 28675162, 27239025, 31054490) and is suspected to be a Saudi founder variant. "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"cggv:254975f0-b3ae-4838-909a-17db2e9faabc_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:254975f0-b3ae-4838-909a-17db2e9faabc_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:3149c09c-d970-4482-9640-f62428631f80","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:59229638-f632-4f76-a620-09489ab0f528","type":"Finding","demonstrates":{"id":"obo:MI_0915"},"dc:description":"tsA-201 cells were transfected with the variant FRRS1L, CPT1C, and GRIA1. Two days after transfection, cells were lysed and membrane vesicles were solubilized. The solubilized protein was immunoprecipitated by anti-GLUA1/A2 antibody and a Western blot was done by anti-FRRS1L antibody. The truncated variant proteins p.Gln321* and p.Val195* were not detected. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28675162","rdfs:label":"Interaction between FRRS1L and  GLUA1/A2"}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0,"dc:description":"This is a variant-level functional data."}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0},{"id":"cggv:254975f0-b3ae-4838-909a-17db2e9faabc_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:54050a21-1d77-4b7f-86c1-1822c4a66c4c","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:aaeff8d4-9d04-4887-8bb4-f6e111836552","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Both experienced seizures, EEG abnormalities, and hypotonia. However, they were different because human neonates did not prematurely die. ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/30692144","type":"dc:BibliographicResource","dc:abstract":"Loss-of-function mutations in a human AMPA receptor-associated protein, ferric chelate reductase 1-like (FRRS1L), are associated with a devastating neurological condition incorporating choreoathetosis, cognitive deficits and epileptic encephalopathies. Furthermore, evidence from overexpression and ","dc:creator":"Stewart M","dc:date":"2019","dc:title":"Loss of "},"rdfs:label":"FRRS1L homozygous knockout"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2}],"evidenceStrength":"Definitive","sequence":9209,"specifiedBy":"GeneValidityCriteria11","strengthScore":14,"subject":{"id":"cggv:23a1ceb3-f4f1-4c6f-884b-6a118e771f7e","type":"GeneValidityProposition","disease":"obo:MONDO_0100062","gene":"hgnc:1362","modeOfInheritance":"obo:HP_0000007"},"version":"1.1","dc:description":"FRRS1L was first reported in relation to autosomal recessive developmental and epileptic encephalopathy (DEE) in 2016 by two groups (Madeo et al., PMID: 27236917; Shaheen et al. PMID: 27239025). Typical phenotypes of individuals affected with FRRS1L-related DEE include severe intractable seizures, global developmental delay, regression, hypotonia, and movement disorders such as choreoathetosis. Eleven homozygous variants (missense and truncations) reported in 11 probands in eight publications are included in this curation (PMIDs: 27236917, 27239025, 28675162, 30525197, 31130284, 33584793, 35815844, 36703223). While a founder variant from Saudi Arabia, NM_014334.4 c.808C>T p.Gln270* (CA10575812), was found in the homozygous state in affected individuals from at least four families in three publications (PMID: 27239025, 27236917, 31054490), only one of the probands was included in the scoring as the level of relatedness between these two families is unclear (PMID: 27239025). Other variants segregated with disease in two different families resulting in a total LOD score of 5.86. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity appears to be loss of function. This gene-disease relationship is also supported by a knockout mouse model that showed spontaneous seizures (PMID: 30692144). In summary, there is definitive evidence supporting the relationship between FRRS1L and autosomal recessive DEE. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification has been approved by ClinGen Epilepsy GCEP on the meeting date, September 17, 2024 (SOP version 11). ","dc:isVersionOf":{"id":"cggv:254975f0-b3ae-4838-909a-17db2e9faabc"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}